Alteplase (r-TPA) vs streptokinase.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Hunt D;Hunt D
  • Source:
    Australian and New Zealand journal of medicine [Aust N Z J Med] 1998 Aug; Vol. 28 (4), pp. 514-7.
  • Publication Type:
    Comparative Study; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Adis Press Country of Publication: Australia NLM ID: 1264322 Publication Model: Print Cited Medium: Print ISSN: 0004-8291 (Print) Linking ISSN: 00048291 NLM ISO Abbreviation: Aust N Z J Med Subsets: MEDLINE
    • Publication Information:
      Publication: Balgowlah, NSW : Adis Press
      Original Publication: Sydney, Royal Australasian College of Physicians,
    • Subject Terms:
      Fibrinolytic Agents/*therapeutic use ; Myocardial Infarction/*drug therapy ; Streptokinase/*therapeutic use ; Tissue Plasminogen Activator/*therapeutic use; Aged ; Aged, 80 and over ; Cerebral Hemorrhage/chemically induced ; Cerebrovascular Disorders/etiology ; Clinical Protocols ; Female ; Fibrinolytic Agents/adverse effects ; Humans ; Male ; Middle Aged ; Myocardial Infarction/complications ; Myocardial Infarction/immunology ; Streptokinase/immunology ; Time Factors ; Tissue Plasminogen Activator/adverse effects
    • Abstract:
      The GUSTO trial and an Australian consensus meeting in 1993 led to the recommendation that recombinant tissue plasminogen activator (r-TPA) was the preferred thrombolytic in patients with acute myocardial infarction (AMI) and ST segment elevation under the age of 75, whose infarction was anterior, who could be treated within four hours of the onset of symptoms and who did not have a contraindication to thrombolysis. Available data suggest that streptokinase (SK) should not be administered in a patient who has received this drug three days or more previously. New data on the risks of stroke confirm that the use of r-TPA is associated with a higher risk of intracranial haemorrhage than SK, and those with a high risk profile for intracranial haemorrhage (hypertension and advanced age) should receive SK rather than r-TPA. It may be justified to give r-TPA to any patient with a large infarct regardless of location, within four hours of the onset of infarction in an attempt to achieve TIMI flow grade 3 (complete) reperfusion, reduce mortality and improve left ventricular function and clinical outcomes. The focus for the future will be on how to treat more patients earlier with thrombolytic agents, rather than the choice of agent.
    • Accession Number:
      0 (Fibrinolytic Agents)
      EC 3.4.- (Streptokinase)
      EC 3.4.21.68 (Tissue Plasminogen Activator)
    • Publication Date:
      Date Created: 19981020 Date Completed: 19981222 Latest Revision: 20190826
    • Publication Date:
      20221213
    • Accession Number:
      10.1111/j.1445-5994.1998.tb02102.x
    • Accession Number:
      9777131